Physician

Abdalla M Sholi, MD

According to 2025 Medicare claims, Abdalla Sholi, MD (NPI: 1275523052) practices hematology/oncology in the Williamsport, PA market, with the plurality of this provider's patient population coming from Lycoming, PA. This provider's primary affiliated billing organization is SUSQUEHANNA PHYSICIAN SERVICES (NPI: 1700962701; TIN: 232449454) and primary practice location at 17701-1909. Sholi is affiliated with the Keystone ACO (ACO ID: A1552), participating under the MSSP model.

Sholi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 422 traditional Medicare patients, billed 1,299 HCPCS/CPT codes, and received $125,168 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,902 prescription claims across 364 beneficiaries totaling $11,152,133 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 38 claims. Open Payments data shows 139 records totaling $136,840. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $88,691 to $125,168. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,186,457 to $11,152,133. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	366	1,388	$88,691
2016	403	1,475	$87,637
2017	386	1,250	$74,424
2018	395	1,352	$84,847
2019	566	1,595	$93,197
2020	297	1,119	$67,310
2021	362	1,310	$121,130
2022	394	1,231	$123,650
2023	447	1,327	$134,809
2024	422	1,299	$125,168

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	148	930	$1,186,457
2016	170	1,276	$2,176,834
2017	175	1,333	$2,828,647
2018	163	1,335	$2,811,090
2019	233	1,039	$2,949,810
2020	254	1,355	$4,334,599
2021	299	1,717	$5,840,091
2022	354	1,940	$9,024,703
2023	374	2,005	$9,688,006
2024	364	1,902	$11,152,133

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	44	$24,451
2016	N/R	86	$29,337
2017	33	116	$29,814
2018	42	136	$17,321
2019	N/R	52	$5,325
2020	N/R	58	$4,187
2021	N/R	20	$2,188
2022	N/R	64	$2,618
2023	N/R	22	$7,895
2024	N/R	38	$794

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	77	77	$135
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	370	1,056	$103
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	16	17	$60
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	17	21	$43
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	76	101	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	115	3,690	$1,893,712
Lenalidomide	Lenalidomide	95	2,534	$1,233,949
Verzenio	Abemaciclib	79	2,212	$1,206,014
Calquence	Acalabrutinib Maleate	67	2,010	$1,023,053
Erleada	Apalutamide	61	1,870	$921,838

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$543
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	20	$251

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	139	$136,840	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abdalla M. Sholi, MD?

Tedicare shows public-source Medicare data for Abdalla M. Sholi, MD (NPI 1275523052), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abdalla M. Sholi, MD have ACO affiliation data?

Abdalla M. Sholi, MD is shown with ACO affiliation data for Keystone ACO (MSSP, ACO ID A1552).

What billing organization is linked to Abdalla M. Sholi, MD?

Abdalla M. Sholi, MD is linked to SUSQUEHANNA PHYSICIAN SERVICES (billing NPI 1700962701) in the available physician profile data.

Does Abdalla M. Sholi, MD have Open Payments data?

Abdalla M. Sholi, MD has 139 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.